Efficacy of three consecutive monthly doses of a topical formulation of selamectin and sarolaner (RevolutionPlus/StrongholdPlus) compared with a single dose of fluralaner (Bravectofor Cats) against induced infestations of Ctenocephalides felis on cats.

Abstract

In a controlled laboratory study, the efficacy against fleas, Ctenocephalides felis, of a single treatment of fluralaner topical solution (Bravectofor Cats, Merck) was compared with that of three consecutive monthly topical treatments with selamectin and sarolaner (RevolutionPlus, Zoetis). Twenty-four domestic short hair cats were ranked based on host suitability flea counts to form groups of three and were randomly assigned within group to one of three treatments. The first group received a topical treatment with (a) placebo (vehicle control for RevolutionPlus) on Days 0, 30, and 60, (b) 6 mg/kg selamectin and 1 mg/kg sarolaner on Days 0, 30, and 60, or (c) 40 mg/kg fluralaner on Day 0 and placebo (vehicle control for RevolutionPlus) on Days 30 and 60. Because doses were rounded off, the selamectin plus sarolaner-treated cats received effective dosages of 5.25-6.60 mg/kg selamectin and 0.88-1.10 mg/kg sarolaner, while the fluralaner-treated cats received dosages of 34.71-43.08 mg/kg fluralaner. All cats were infested with 100 (±5) fleas on Day -1 and at biweekly intervals after that, from Day 13 to Day 89. Flea comb counts were conducted 24 hours after treatment or after re-infestation. There were no adverse events related to treatment during the study. Except for a single cat from which 20 fleas were recovered on Day 90, all other placebo-treated cats had at least 48 fleas at each count, indicating adequacy of infestation of the controls. Based on geometric mean live flea counts, three consecutive monthly treatments with RevolutionPlus resulted in consistent and high efficacy of ≥98.6% compared with placebo throughout the study. A single treatment with Bravectofor Cats provided consistent and high efficacy of ≥94.6% on all count days during a period of 12 weeks, the approved duration of efficacy for the product. Based on the efficacy results of the study, both products were equivalent in their ability to control fleas on cats. Use of Bravectofor Cats every 12 weeks or the consecutive monthly use of RevolutionPlus is expected to provide extended high residual kill over the respective labeled durations of efficacy of the two products.